Inhibition of EGLN1 compromises tRCC cell growth by stabilizing HIF-1a and promoting metabolic reprogramming away from OXPHOS, thus representing a vulnerability to OXPHOS-dependent tRCC cells. Here, EGLN1 is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.